Translational autoimmunity in pemphigus and the role of novel Bruton tyrosine kinase inhibitors

Translational autoimmunity in pemphigus and the role of novel Bruton tyrosine kinase inhibitors

Bruton tyrosine kinase (BTK) is involved in a multifarious inflammatory and autoimmune process. As a result, BTK has emerged as a promising novel remedial target for amalgamated autoimmune diseases. Medicament corporations have recently devoted considerable attention to the evolution of BTK inhibito...

Full description

Bibliographic Details
Main Author:	Piyu Parth Naik
Format:	Article
Language:	English
Published:	Elsevier 2022-01-01
Series:	Journal of Translational Autoimmunity
Subjects:	Bruton tyrosine kinase B-cell signaling Autoimmunity Pemphigus BTK inhibition
Online Access:	http://www.sciencedirect.com/science/article/pii/S258990902200017X

Similar Items

Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus
by: Aikaterini Patsatsi, et al.
Published: (2021-08-01)

Efficacy and safety of Bruton's tyrosine kinase inhibitors in the treatment of pemphigus: A comprehensive literature review and future perspective
by: Yekta Ghane, et al.
Published: (2023-12-01)

Role of Bruton’s Tyrosine Kinase in Stage III Colorectal Cancer
by: Debora Basile, et al.
Published: (2019-06-01)

Targeting Bruton’s Tyrosine Kinase in Inflammatory and Autoimmune Pathologies
by: Stefan F. H. Neys, et al.
Published: (2021-06-01)

Bruton’s Tyrosine Kinase Inhibitors: A New Generation of Promising Agents for Multiple Sclerosis Therapy
by: Antonio García-Merino
Published: (2021-09-01)

Design, synthesis and evaluation of a series of potential prodrugs of a Bruton’s tyrosine kinase (BTK) inhibitor
by: Zhou-Peng Xiao, et al.
Published: (2023-03-01)

Molecular Drug Discovery of Single Ginsenoside Compounds as a Potent Bruton’s Tyrosine Kinase Inhibitor
by: Keun Woo Lee, et al.
Published: (2020-04-01)

Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials
by: Dariusz Rozkiewicz, et al.
Published: (2023-03-01)

Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma
by: Max Von Suskil, et al.
Published: (2021-05-01)

Structural Complementarity of Bruton’s Tyrosine Kinase and Its Inhibitors for Implication in B-Cell Malignancies and Autoimmune Diseases
by: Asim Najmi, et al.
Published: (2023-03-01)

Bruton’s Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures
by: Garth E. Ringheim, et al.
Published: (2021-11-01)

Specific Expression of a New Bruton Tyrosine Kinase Isoform (p65BTK) in the Glioblastoma Gemistocytic Histotype
by: Luca Sala, et al.
Published: (2019-01-01)

Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice
by: Caroline E. O'Riordan, et al.
Published: (2019-09-01)

Bruton’s Tyrosine Kinase Supports Gut Mucosal Immunity and Commensal Microbiome Recognition in Autoimmune Arthritis
by: Rachel H. Bonami, et al.
Published: (2022-03-01)

PENAPISAN VIRTUAL BERBASIS STRUKTUR DARI DATABASE BAHAN ALAM ZINC SEBAGAI INHIBITOR BRUTON TYROSINE KINASE
by: Fauzan Zein Muttaqin, et al.
Published: (2019-10-01)

PENAPISAN VIRTUAL BERBASIS STRUKTUR DARI DATABASE BAHAN ALAM ZINC SEBAGAI INHIBITOR BRUTON TYROSINE KINASE
by: Fauzan Zein Muttaqin, et al.
Published: (2019-10-01)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
by: Obada Ababneh, et al.
Published: (2022-05-01)

Bruton’s Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis
by: Neeta Garg, et al.
Published: (2022-10-01)

Bruton’s Tyrosine Kinase-Mediated Signaling in Myeloid Cells Is Required for Protective Innate Immunity During Pneumococcal Pneumonia
by: Alexander P. de Porto, et al.
Published: (2021-09-01)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
by: Abdullah Mohammad Khan
Published: (2022-04-01)

X-Linked Immunodeficient Mice With No Functional Bruton's Tyrosine Kinase Are Protected From Sepsis-Induced Multiple Organ Failure
by: Caroline E. O'Riordan, et al.
Published: (2020-10-01)

Immunomodulating effects of antitumor drugs Bruton tyrosine kinase inhibitors and the possibility of their use in allergic and infectious diseases
by: Yu. S. Torshina, et al.
Published: (2023-06-01)

Highly selective inhibition of Bruton’s tyrosine kinase attenuates skin and brain disease in murine lupus
by: Samantha A. Chalmers, et al.
Published: (2018-01-01)

Discovery of 5-Phenoxy-2-aminopyridine Derivatives as Potent and Selective Irreversible Inhibitors of Bruton’s Tyrosine Kinase
by: Eun Lee, et al.
Published: (2020-10-01)

Bruton’s Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?
by: Lorenzo-Vizcaya A, et al.
Published: (2020-06-01)

Research-based flow cytometry assays for pathogenic assessment in the human B-cell biology of gene variants revealed in the diagnosis of inborn errors of immunity: a Bruton’s tyrosine kinase case-study
by: L. del Pino-Molina, et al.
Published: (2023-04-01)

Bruton’s tyrosine kinase inhibition limits endotoxic shock by suppressing IL-6 production by marginal zone B cells in mice
by: Kazuhiko Kawata, et al.
Published: (2024-04-01)

A mechanism for localized dynamics-driven activation in Bruton's tyrosine kinase
by: Simei Qiu, et al.
Published: (2021-08-01)

Targeting Multiple End Organs in Lupus and Other Systemic Rheumatic Diseases by Inhibiting Bruton’s Tyrosine Kinase
by: Yong Du, et al.
Published: (2022-07-01)

Non-Covalent Bruton’s Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia
by: Skye Montoya, et al.
Published: (2023-07-01)

"Screening of the Bruton Tyrosine Kinase (BTK) Gene Mutations in 13 Iranian Patients with Presumed X-Linked Agammaglobulinemia "
by: "Asghar Aghamohammadi, et al.
Published: (2004-12-01)

The Possible Role of Bruton Tyrosine Kinase Inhibitors in the Treatment of COVID-19: A Review
by: Mitra Rezaei, MD, et al.
Published: (2022-01-01)

Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review
by: Zemene Demelash Kifle
Published: (2021-09-01)

Targeting Bruton’s tyrosine kinase in vitreoretinal lymphoma: an open-label, prospective, single-center, phase 2 study
by: Wenxue Guan, et al.
Published: (2022-11-01)

Mutations of Bruton's tyrosine kinase gene in Brazilian patients with X-linked agammaglobulinemia
by: V.D. Ramalho, et al.
Published: (2010-09-01)

Development of a novel Bruton’s tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells
by: Weam Othman Elbezanti, et al.
Published: (2022-09-01)

Targeting Bruton Tyrosine Kinase: A novel strategy in the treatment of B-cell lymphomas
by: Sklavenitis-Pistofidis R., et al.
Published: (2017-06-01)

Inhibition of Bruton's Tyrosine Kinase Protects Against Burn Sepsis-Induced Intestinal Injury
by: Jia Wan, et al.
Published: (2022-02-01)

A novel Bruton's tyrosine kinase inhibitor JDB175 shows potent efficacy to suppress central nervous system lymphoma
by: Yong Xia, et al.
Published: (2023-12-01)

Bruton’s Tyrosine Kinase Inhibitors: Recent Updates
by: Amneh Fares, et al.
Published: (2024-02-01)